Recovery Still Some Way Off For Evotec

The German firm will have to wait until 2025 for a reversal in its fortunes as new CEO Christian Wojczewski accelerates its transformation program with the loss of 400 jobs.

Bump In The Road For Evotec • Source: Shutterstock

2024 continues to be a tricky year for German biotech Evotec SE, as difficult market conditions hamper its turnaround endeavors. It now plans cut around 400 jobs, exit gene therapy and close its site in Orth, Austria, as it redoubles its reorganization efforts.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Can European Biotech Survive And Thrive In Era Of Instability?

30 Apr 2025

• By Andrew McConaghie

Europe's biopharma sector could suffer if the Trump administration incentivizes US investment but VC leaders believe the region can still thrive and potentially capitalize on instability elsewhere.